Literature DB >> 3006857

Kadsurenone distinguishes between different platelet activating factor receptor subtypes on macrophages and polymorphonuclear leucocytes.

G Lambrecht, M J Parnham.   

Abstract

The effects of the antagonist kadsurenone on the platelet activating factor (Paf)-induced chemiluminescence of guinea-pig peritoneal macrophages and on pig peripheral blood leucocyte aggregation were compared. Linearity and slopes of unity of the Schild plots confirmed the competitive nature of the antagonism by kadsurenone. pA2 values indicated a 91 fold lower affinity of kadsurenone for leucocyte Paf receptors than for those in macrophages. It is concluded that these two types of Paf receptors are not identical and are provisionally designated Paf1 and Paf2 receptors, respectively.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3006857      PMCID： PMC1916546          DOI： 10.1111/j.1476-5381.1986.tb10816.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  8 in total

Review 1.  pA2 and receptor differentiation: a statistical analysis of competitive antagonism.

Authors:  R J Tallarida; A Cowan; M W Adler
Journal:  Life Sci       Date:  1979-08-20       Impact factor: 5.037

Review 2.  Biology and biochemistry of platelet-activating factor.

Authors:  J T O'Flaherty; R L Wykle
Journal:  Clin Rev Allergy       Date:  1983-09

3.  Platelet activating factor (PAF) induces the oxidative burst in macrophages.

Authors:  H P Hartung; M J Parnham; J Winkelmann; W Englberger; U Hadding
Journal:  Int J Immunopharmacol       Date:  1983

4.  Novel effects of 1-O-hexadecyl-2-acyl-sn-glycero-3-phosphorycholine mediators on human leukocyte function: delineation of the specific roles of the acyl substituents.

Authors:  E J Goetzl; C K Derian; A I Tauber; F H Valone
Journal:  Biochem Biophys Res Commun       Date:  1980-06-16       Impact factor: 3.575

5.  Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects.

Authors:  T Y Shen; S B Hwang; M N Chang; T W Doebber; M H Lam; M S Wu; X Wang; G Q Han; R Z Li
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

6.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

7.  Activation of human neutrophils with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycerol-3-phosphorylcholine (platelet activating factor).

Authors:  J O Shaw; R N Pinckard; K S Ferrigni; L M McManus; D J Hanahan
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

8.  Immunization of dissociated spleen cell cultures from normal mice.

Authors:  R I Mishell; R W Dutton
Journal:  J Exp Med       Date:  1967-09-01       Impact factor: 14.307
  8 in total
  14 in total

1.  Effects of PAF and PAF antagonists on the shape of venous endothelial cells in vitro.

Authors:  A M Northover
Journal:  Agents Actions       Date:  1989-08

2.  Antagonism of platelet activating factor-induced chemiluminescence in guinea-pig peritoneal macrophages in differing states of activation.

Authors:  M J Parnham; C Bittner; G Lambrecht
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

3.  Influence of plasma protein content and platelet number on the potency of PAF and its antagonist RP 59227 in rabbit platelet preparations.

Authors:  A Floch; I Cavero
Journal:  Br J Pharmacol       Date:  1990-05       Impact factor: 8.739

4.  Differential actions of platelet-activating factor (PAF) receptor antagonists on the vasodilator and vasoconstrictor effects of PAF in the rat perfused heart.

Authors:  W M Hu; R Y Man
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

5.  1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine: an analogue of platelet-activating factor with partial agonist activity.

Authors:  G Grigoriadis; A G Stewart
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

Review 6.  pA2 values for antagonists of platelet activating factor on aggregation of rabbit platelets.

Authors:  S R O'Donnell; C J Barnett
Journal:  Br J Pharmacol       Date:  1988-06       Impact factor: 8.739

7.  Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats.

Authors:  S W Chang; C O Feddersen; P M Henson; N F Voelkel
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

8.  Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.

Authors:  R Korth; M Hirafuji; C L Keraly; D Delautier; J Bidault; J Benveniste
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

9.  Platelet-activating factor-mediated transmembrane signaling in human B lymphocytes is regulated through a pertussis- and cholera toxin-sensitive pathway.

Authors:  B D Mazer; H Sawami; A Tordai; E W Gelfand
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

10.  Effects of REV 5901, a 5-lipoxygenase inhibitor and leukotriene antagonist, on pulmonary responses to platelet activating factor in the guinea-pig.

Authors:  G Anderson; M Fennessy
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.